Bausch Health Companies Inc.
BHCBausch Health Companies Inc. (formerly Valeant and ICN Pharmaceuticals) is a global, diversified Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic pharmaceuticals, and over-the-counter products directly or indirectly in more than 90 countries and regions, including the United States, Canada, Europe, the Middle East, Africa, Asia Pacific and Latin America.
Drugs in Pipeline
71
Phase 3 Programs
48
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How BHC's past catalysts played out
budesonide-MMX® 6 mg
Ulcerative Colitis
Viramidine
Chronic Hepatitis C
IDP 121 Lotion
Acne
210 mg brodalumab
Psoriatic Arthritis
Balsalazide disodium
Inflammatory Bowel Disease
IDP-122 Lotion
Plaque Psoriasis
Budesonide MMX® 6 mg
Ulcerative Colitis
Tramadol HCl ER
Chronic Pain
Budesonide MMX 6 mg Tablet
Ulcerative Colitis
IDP-120 Gel
Acne Vulgaris
Neuromultivit
Vertebrogenic Radiculopathy L5, S1
IDP-122 Vehicle Lotion
Psoriasis
Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks
Chronic Hepatitis C
Crofelemer 125 mg
HIV Associated Diarrhea
Budesonide MMX®
Ulcerative Colitis
IDP-120 Vehicle Gel
Acne Vulgaris
Budesonide
Proctitis
SC Methylnaltrexone
Terminal Illness
IDP-118 Vehicle Lotion
Plaque Psoriasis
tramadol ER
Chronic Pain
tramadol HCl ER; celecoxib
Chronic Pain
Encapsulated Mesalamine Granules (eMG)
Ulcerative Colitis
MOA-728
Constipation
IDP-126 Vehicle Gel
Acne Vulgaris
IDP-123 Vehicle Lotion
Acne Vulgaris
Granulated mesalamine
Ulcerative Colitis
Larsucosterol
Hepatitis
Methylnaltrexone (MOA-728)
Post Operative Bowel Dysfunction
Bisacodyl
Chronic Idiopathic Constipation
Ribavirin
Chronic Hepatitis C
IDP-121 Lotion
Acne
open-label rifaximin
Irritable Bowel Syndrome With Diarrhea
Plecanatide
Chronic Idiopathic Constipation
5 ASA, enemas, suppositories, corticosteroids
Ulcerative Colitis
ACYC
Acne
SC Methylnaltrexone (MNTX)
Terminal Illness
IDP-126 Gel
Acne Vulgaris
IDP-118 Lotion
Plaque Psoriasis
IDP-124 Lotion
Atopic Dermatitis
IDP-124 Vehicle Lotion
Atopic Dermatitis
Rifaximin (Xifaxan)
Clostridium Infections
Rifaximin
Irritable Bowel Syndrome
Methylnaltrexone
Constipation
Rifaximin SSD
Hepatic Encephalopathy
N-methylnaltrexone bromide (MOA-728)
Constipation
Omeprazole sodium bicarbonate immediate release PWD/FS
Upper Gastrointestinal Bleeding
crofelemer
Irritable Bowel Syndrome
IDP-123 Lotion
Acne Vulgaris
SP-333 1 mg
Constipation
Taribavirin
Chronic Hepatitis C
IDP-118 Vehicle Cream
Psoriasis
IDP-118 Monad HP Lotion
Plaque Psoriasis
IDP-126 Component A
Acne Vulgaris
Mesalamine Granules 750 mg
Irritable Bowel Syndrome With Diarrhea
SP-304 0.3 mg
Chronic Idiopathic Constipation
Tazorac Cream
Psoriasis
SC MNTX
Bowel Dysfunction
pradefovir mesylate
Hepatitis B, Chronic
Low Dose Rifaximin ER
Sickle Cell Disease
IDP 120 Component A Gel
Acne Vulgaris
Low Dose MT-1303
Ulcerative Colitis
IV Methylnaltrexone
Healthy Volunteers
1.2% JNJ 10229570-AAA
Acne Vulgaris
Methylnaltrexone bromide
Opioid-induced Constipation
IV Methylnaltrexone (MNTX)
Postoperative Ileus
Retigabine
Postherpetic Neuralgia
40 mg Rifaximin SSD once daily
Overt Hepatic Encephalopathy
SAN-300 0.5 mg/kg QW
Rheumatoid Arthritis
70 mg SC
Psoriasis
Rifaximin SSD 40 mg IR tablet
Liver Cirrhosis
Retin-A Micro 0.04% facial acne treatment
Acne Vulgaris
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
budesonide-MMX® 6 mg | Phase 3 | Ulcerative Colitis | - | - |
Viramidine | Phase 3 | Chronic Hepatitis C | - | - |
IDP 121 Lotion | Phase 3 | Acne | - | - |
210 mg brodalumab | Phase 3 | Psoriatic Arthritis | - | - |
Balsalazide disodium | Phase 3 | Inflammatory Bowel Disease | - | - |
IDP-122 Lotion | Phase 3 | Plaque Psoriasis | - | - |
Budesonide MMX® 6 mg | Phase 3 | Ulcerative Colitis | - | - |
Tramadol HCl ER | Phase 3 | Chronic Pain | - | - |
Budesonide MMX 6 mg Tablet | Phase 3 | Ulcerative Colitis | - | - |
IDP-120 Gel | Phase 3 | Acne Vulgaris | - | - |
Neuromultivit | Phase 3 | Vertebrogenic Radiculopathy L5, S1 | - | - |
IDP-122 Vehicle Lotion | Phase 3 | Psoriasis | - | - |
Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks | Phase 3 | Chronic Hepatitis C | - | - |
Crofelemer 125 mg | Phase 3 | HIV Associated Diarrhea | - | - |
Budesonide MMX® | Phase 3 | Ulcerative Colitis | - | - |
IDP-120 Vehicle Gel | Phase 3 | Acne Vulgaris | - | - |
Budesonide | Phase 3 | Proctitis | - | - |
SC Methylnaltrexone | Phase 3 | Terminal Illness | - | - |
IDP-118 Vehicle Lotion | Phase 3 | Plaque Psoriasis | - | - |
tramadol ER | Phase 3 | Chronic Pain | - | - |
tramadol HCl ER; celecoxib | Phase 3 | Chronic Pain | - | - |
Encapsulated Mesalamine Granules (eMG) | Phase 3 | Ulcerative Colitis | - | - |
MOA-728 | Phase 3 | Constipation | - | - |
IDP-126 Vehicle Gel | Phase 3 | Acne Vulgaris | - | - |
IDP-123 Vehicle Lotion | Phase 3 | Acne Vulgaris | - | - |
Granulated mesalamine | Phase 3 | Ulcerative Colitis | - | - |
Larsucosterol | Phase 3 | Hepatitis | - | - |
Methylnaltrexone (MOA-728) | Phase 3 | Post Operative Bowel Dysfunction | - | - |
Bisacodyl | Phase 3 | Chronic Idiopathic Constipation | - | - |
Ribavirin | Phase 3 | Chronic Hepatitis C | - | - |
IDP-121 Lotion | Phase 3 | Acne | - | - |
open-label rifaximin | Phase 3 | Irritable Bowel Syndrome With Diarrhea | - | - |
Plecanatide | Phase 3 | Chronic Idiopathic Constipation | - | - |
5 ASA, enemas, suppositories, corticosteroids | Phase 3 | Ulcerative Colitis | - | - |
ACYC | Phase 3 | Acne | - | - |
SC Methylnaltrexone (MNTX) | Phase 3 | Terminal Illness | - | - |
IDP-126 Gel | Phase 3 | Acne Vulgaris | - | - |
IDP-118 Lotion | Phase 3 | Plaque Psoriasis | - | - |
IDP-124 Lotion | Phase 3 | Atopic Dermatitis | - | - |
IDP-124 Vehicle Lotion | Phase 3 | Atopic Dermatitis | - | - |
Rifaximin (Xifaxan) | Phase 3 | Clostridium Infections | - | - |
Rifaximin | Phase 3 | Irritable Bowel Syndrome | - | - |
Methylnaltrexone | Phase 3 | Constipation | - | - |
Rifaximin SSD | Phase 3 | Hepatic Encephalopathy | - | - |
N-methylnaltrexone bromide (MOA-728) | Phase 3 | Constipation | - | - |
Omeprazole sodium bicarbonate immediate release PWD/FS | Phase 3 | Upper Gastrointestinal Bleeding | - | - |
crofelemer | Phase 3 | Irritable Bowel Syndrome | - | - |
IDP-123 Lotion | Phase 3 | Acne Vulgaris | - | - |
SP-333 1 mg | Phase 2 | Constipation | - | - |
Taribavirin | Phase 2 | Chronic Hepatitis C | - | - |
IDP-118 Vehicle Cream | Phase 2 | Psoriasis | - | - |
IDP-118 Monad HP Lotion | Phase 2 | Plaque Psoriasis | - | - |
IDP-126 Component A | Phase 2 | Acne Vulgaris | - | - |
Mesalamine Granules 750 mg | Phase 2 | Irritable Bowel Syndrome With Diarrhea | - | - |
SP-304 0.3 mg | Phase 2 | Chronic Idiopathic Constipation | - | - |
Tazorac Cream | Phase 2 | Psoriasis | - | - |
SC MNTX | Phase 2 | Bowel Dysfunction | - | - |
pradefovir mesylate | Phase 2 | Hepatitis B, Chronic | - | - |
Low Dose Rifaximin ER | Phase 2 | Sickle Cell Disease | - | - |
IDP 120 Component A Gel | Phase 2 | Acne Vulgaris | - | - |
Low Dose MT-1303 | Phase 2 | Ulcerative Colitis | - | - |
IV Methylnaltrexone | Phase 2 | Healthy Volunteers | - | - |
1.2% JNJ 10229570-AAA | Phase 2 | Acne Vulgaris | - | - |
Methylnaltrexone bromide | Phase 2 | Opioid-induced Constipation | - | - |
IV Methylnaltrexone (MNTX) | Phase 2 | Postoperative Ileus | - | - |
Retigabine | Phase 2 | Postherpetic Neuralgia | - | - |
40 mg Rifaximin SSD once daily | Phase 2 | Overt Hepatic Encephalopathy | - | - |
SAN-300 0.5 mg/kg QW | Phase 2 | Rheumatoid Arthritis | - | - |
70 mg SC | Phase 2 | Psoriasis | - | - |
Rifaximin SSD 40 mg IR tablet | Phase 2 | Liver Cirrhosis | - | - |
Retin-A Micro 0.04% facial acne treatment | Phase 2 | Acne Vulgaris | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Bausch Health Companies Inc.'s drug pipeline?→
CatalystAlert tracks 71 drug candidates in Bausch Health Companies Inc.'s (BHC) pipeline across Phase 3, Phase 2. Its lead program is budesonide-MMX® 6 mg (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Bausch Health Companies Inc.'s next FDA catalyst?→
Bausch Health Companies Inc.'s (BHC) next tracked catalyst is a Earnings expected July 29, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BHC biotech catalysts?→
Add BHC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Bausch Health Companies Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.